Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05999994 · ClinicalTrials.gov registry record · Phase 2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
A Phase 2 study of Neoplasms and Adolescent, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 20
- Study locations
NCT05999994 is a Phase 2 study of Neoplasms and Adolescent that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 105 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT05999994, a Phase 2 study of Neoplasms and Adolescent, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Docetaxel
- DRUG Gemcitabine
- DRUG Ramucirumab
- DRUG Vinorelbine
Study Locations (20)
California
- Childrens Hospital of Los Angeles - Los Angeles
- UCLA Medical Center - Los Angeles
- Children's Hospital of Orange County - Orange
Arizona
- Phoenix Children's Hospital - Phoenix
- Phoenix Children's Hospital - Phoenix
Florida
- Golisano Children's Hospital of Southwest Florida - Fort Myers
- Mayo Clinic in Florida - Jacksonville
Missouri
- Children's Mercy Hospital - Kansas City
- Washington University Medical School - St Louis
Alabama
- Childrens Hospital of Alabama - Birmingham
Colorado
- Children's Hospital of Colorado - Denver
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta, Inc. at Egleston - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2020-01-22 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05999994
The ClinicalTrials.gov registry entry for NCT05999994 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (94% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05999994 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT05999994 about?
NCT05999994 is a clinical study titled "A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer". The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New stud...
What is the current status of trial NCT05999994?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2020-01-22. Estimated completion is 2027-05.
What conditions does trial NCT05999994 study?
This clinical trial studies the following conditions: Neoplasms, Adolescent, Child.
What interventions are being tested in trial NCT05999994?
The interventions under investigation include: Cyclophosphamide (DRUG), Docetaxel (DRUG), Gemcitabine (DRUG), Ramucirumab (DRUG), Vinorelbine (DRUG).
Who is sponsoring clinical trial NCT05999994?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05999994 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
-
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
RECRUITING · Phase 2
-
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
RECRUITING · Phase 2
-
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.